Volc Volc D D Poewe Poewe W W Kutzelnigg Kutzelnigg A A Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial Lancet Neurol Lancet Neurol 2020 2020 19 19 591 591 600 600 supplied-pmid 32562684? Here, SNCA is linked to Parkinson disease.